Objective: This study aims to review the alteration of plasma nesfatin-1 levels in patients with depression.Methods: Under the guidance of the latest PRISMA checklist, a systematic review and meta-analysis were conducted by searching English database (PubMed, Web of Science, EMDASE) and Chinese database for relevant studies up to August, 2019. Pooled standardised mean difference (SMD) with 95% confidence intervals (CI) was calculated with the random effects model.Results: Nine studies that reported the association between plasma levels of nesfatin-1 and the risk of depression with 567 patients and 447 control participants were included in the meta-analysis. Compared with the healthy controls, depressive patients had a higher plasma level of nesfatin-1 [SMD (95% CI):1.58(0.75, 2.41), Z = 3.74, p for Z < 0.001; I2 = 96.8%, p for I2 < 0.001]. The subgroup analyses and meta-regression failed to find the source of the heterogeneity. No evidence of publication bias was found either in Begg's test (p = 0.348) or the Egger's test (p = 0.523).Conclusion: The present meta-analysis indicated that a higher plasma level of nesfatin-1 was associated with an increased risk of depression.

中文翻译：

---

nesfatin-1的血浆水平是亚洲人抑郁症的新生物标志物：荟萃分析的证据。

目的：本研究旨在回顾抑郁症患者血浆nesfatin-1水平的变化。方法：在最新的PRISMA检查表的指导下，通过搜索英文数据库进行系统的回顾和荟萃分析（PubMed，Web of Science） ，EMDASE）和截至2019年8月的相关研究的中文数据库。使用随机效应模型计算了95％置信区间（CI）的合并标准均值（SMD）。结果：九项研究报告了血浆血浆水平之间的相关性。荟萃分析包括nesfatin-1和567名患者和447名对照参与者的抑郁风险。与健康对照组相比，抑郁症患者的nesfatin-1血浆水平更高[SMD（95％CI）：1.58（0.75，2.41），Z = 3.74，p <Z = 0.001；I2 = 96.8％，I2 <0.001的p]。亚组分析和元回归未能找到异质性的来源。在Begg检验（p = 0.348）或Egger检验（p = 0.523）中均未发现任何发表偏倚的证据。结论：本荟萃分析表明，nesfatin-1的血浆水平升高与患病风险增加有关。萧条。